Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Subhanu Saxena

    Jump to

    • Cipla Q1 profit down 44%, US biz drags revenue; MD to step down

    • Cipla launches generic hepatitis C drug in India

    • Cipla to pay for InvaGen, Exelan mostly through own funds

    • Cipla to acquire two US pharma companies for $550 mn

    • Aiming to achieve 70-80% organic growth: Cipla

    • Cipla falls 5% on fears of Nexium sales slowdown post Q1

    • Cipla sees senior, mid-mgmt level exodus in last 3-4 months

    • Cipla to sharpen focus on emerging markets in growth push

    • Cipla gets USFDA nod for Lopinavir, Ritonavir oral pellets

    • Cipla to launch generic Hepatitis C drug 'Hepcvir' in India

    • Cipla awarded $188.95mn tender by Global Fund for ARV drugs

    • Cipla forms JV in Morocco to expand position in African mkt

    • Discussing partnerships, have done in-licensing deals:Cipla

    • Respiratory business expected to double in future: Cipla

    • Cipla appoints Sameer Goel as India Head

    • Cipla acquires Croatia-based Celeris

    • H1 inline; Cipla Medpro fully integrated: Cipla MD

    • Cipla appoints MK Hamied as Executive Vice-Chairman

      Indian drug major Cipla announced M K Hamied as the executive vice chairman with effect from tomorrow. Subhanu Saxena will take over as the managing director and global CEO.

    • Medpro buy to boost Africa biz sales by 2-3%: Cipla

      Cipla's acquisition of South Africa's Cipla Medpro will boost Africa business revenue by 2-3 percent, Subhanu Saxena, CEO said on Thursday.

    • Cipla mgmt rejig: Time to act as godfather says YK Hamied

      Dr.YK Hamied, CMD, Cipla will retire with effect on March 31.Talking to CNBC-TV18 about his retirement plans, YK Hamied, CMD, Cipla says, “We now have built up a very strong senior management team and time has come to let the youngsters‘ takeover.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347